Lysoway Therapeutics Inc. announced that it has received a research grant of $2.93 million from The Michael J. Fox Foundation for Parkinson's Research. The funding will support the preclinical development of Lysoway’s highly brain-penetrant small molecule mucolipin TRP Cation channel 1 (MCOLN1/TRPML1) agonist.

In the tumor microenvironment, cancer cells activate various signaling pathways to promote their growth. This includes the formation of blood vessels. However, the circulatory system is not the only one attracted to the tumor. Researchers at Sanford Research have uncovered a mechanism to circumvent the immune response that would destroy them.

At the Alzheimer's Association International Conference (AAIC) 2025, researchers from Acadia Pharmaceuticals Inc. have presented novel results on the assessment of the pharmacologic and pharmacokinetic (PK) properties and nonclinical safety of ACP-204.

In Alzheimer’s disease (AD), degeneration of synapses, including synaptic spines, has been linked to cognitive losses.

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding subtypes in Alzheimer’s disease is all but imperative. Prior to the approval of the modestly effective Lequembi (lecanemab, Biogen Inc./Eisai Co. Ltd.) Kisunla (donanemab, Eli Lilly and Co.), and the since-withdrawn Aduhelm (aducanumab, Biogen Inc./Eisai Co. Ltd.), more than a dozen failed phase III clinical trials were all that amyloid-targeting drugs had to show for themselves for decades of effort.

Researchers from Suven Life Sciences Ltd. have presented results on the evaluation of the pharmacological properties of SUVN-I6107 in various animal models of cognitive deficits at the Alzheimer's Association International Conference (AAIC) 2025.

Cassava Sciences Inc. a has reported positive preclinical results of a study evaluating simufilam in a mouse model of tuberous sclerosis complex (TSC)-related epilepsy. TSC is a rare genetic disorder resulting from a mutation in the TSC1 or TSC2 gene.

Neuroinflammation is a hallmark of Alzheimer’s disease (AD), driven in part by chronic microglial activation and elevated pro-inflammatory cytokines, which contribute to neuronal damage and cognitive decline. Targeting microglial activity has emerged as a promising therapeutic approach.